×
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
NASDAQ:IDXX

IDEXX Laboratories Stock Forecast, Price & News

$358.22
+9.01 (+2.58%)
(As of 06/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$342.69
$361.92
50-Day Range
$327.37
$492.52
52-Week Range
$318.50
$706.95
Volume
683,115 shs
Average Volume
620,968 shs
Market Capitalization
$30.09 billion
P/E Ratio
42.00
Dividend Yield
N/A
Price Target
$628.86
30 days | 90 days | 365 days | Advanced Chart

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock Forecast (MarketRank)

Overall MarketRank

2.36 out of 5 stars

Medical Sector

227th out of 1,432 stocks

Diagnostic Substances Industry

3rd out of 27 stocks

Analyst Opinion: 3.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
IDEXX Laboratories logo

About IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDXX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
10,350
Year Founded
1983

Company Calendar

Last Earnings
5/04/2022
Today
6/29/2022
Next Earnings (Estimated)
7/29/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$628.86
High Stock Price Forecast
$770.00
Low Stock Price Forecast
$470.00
Forecasted Upside/Downside
+75.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.66666666666667
Research Coverage
9 Analysts

Profitability

Net Income
$744.84 million
Pretax Margin
27.61%

Debt

Sales & Book Value

Annual Sales
$3.22 billion
Cash Flow
$9.93 per share
Book Value
$8.14 per share

Miscellaneous

Free Float
82,276,000
Market Cap
$30.09 billion
Optionable
Optionable
Beta
1.11

Social Links















IDEXX Laboratories Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IDEXX Laboratories stock.
View analyst ratings for IDEXX Laboratories
or view top-rated stocks.

What is IDEXX Laboratories' stock price forecast for 2022?

9 Wall Street analysts have issued 1-year price objectives for IDEXX Laboratories' shares. Their IDXX stock forecasts range from $470.00 to $770.00. On average, they predict IDEXX Laboratories' stock price to reach $628.86 in the next year. This suggests a possible upside of 75.6% from the stock's current price.
View analysts' price targets for IDEXX Laboratories
or view top-rated stocks among Wall Street analysts.

How has IDEXX Laboratories' stock price performed in 2022?

IDEXX Laboratories' stock was trading at $658.46 at the start of the year. Since then, IDXX stock has decreased by 45.6% and is now trading at $358.22.
View the best growth stocks for 2022 here
.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Friday, July 29th 2022.
View our earnings forecast for IDEXX Laboratories
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings data on Wednesday, May, 4th. The company reported $2.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.25 by $0.02. The business had revenue of $836.55 million for the quarter, compared to analyst estimates of $836.47 million. IDEXX Laboratories had a net margin of 22.43% and a trailing twelve-month return on equity of 103.70%. IDEXX Laboratories's quarterly revenue was up 7.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.35 EPS.
View IDEXX Laboratories' earnings history
.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $8.11-$8.35 for the period, compared to the consensus earnings per share estimate of $9.44. The company issued revenue guidance of $3.39 billion-$3.46 billion, compared to the consensus revenue estimate of $3.54 billion.

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the following people:
  • Mr. Jonathan J. Mazelsky, Pres, CEO & Director (Age 61, Pay $3.07M) (LinkedIn Profile)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 60, Pay $1.43M) (LinkedIn Profile)
  • Mr. James F. Polewaczyk, Exec. VP & Chief Commercial Officer (Age 58, Pay $1.19M) (LinkedIn Profile)
  • Mr. Michael J. Lane, Exec. VP and GM of Reference Laboratories & Information Technology (Age 54, Pay $1.19M) (LinkedIn Profile)
  • Dr. Nimrata Khatra Hunt P.E., Ph.D., Exec. VP and GM - Point of Care Diagnostics & Worldwide Operations (Age 54, Pay $1.18M)
  • Mr. John Hart, Sr. VP of Worldwide Operations
  • Mr. Jeffery D. Chadbourne, Sr. Director of Accounting & Financial Reporting (Age 46)
  • Dr. Martin Smith Ph.D., Exec. VP & CTO (Age 54)
  • Mr. Ken Grady, Sr. VP & Chief Information Officer
  • Ms. Sharon E. Underberg, Exec. VP, Gen. Counsel, & Corp. Sec. (Age 61)

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories CEO Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among IDEXX Laboratories' employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Square (SQ), Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $358.22.

How much money does IDEXX Laboratories make?

IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $30.09 billion and generates $3.22 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $8.529990 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

IDEXX Laboratories employs 10,350 workers across the globe.

When was IDEXX Laboratories founded?

IDEXX Laboratories was founded in 1983.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for IDEXX Laboratories is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at [email protected], or via fax at 207-556-4346.

This page (NASDAQ:IDXX) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.